HOVON150AML
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
- NCT03839771 ↗
- Active, not recruiting
- Stichting Hemato-Oncologie voor Volwassenen Nederland
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 1 | |
| X threads | 1 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy.
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2
- Interventions
- AG-120; Placebo for AG-120; AG-221; Placebo for AG-221
- Arms
- Arm A: Placebo · Placebo comparator
- Arm B: Ivosidenib (IDH1) or Enasidenib (IDH2) · Experimental
- Enrollment
- 968 (estimated)
- Primary outcomes
- Event-free survival (EFS)
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland with University of Ulm
- Start
- Mar 1, 2019
- Primary completion
- Apr 17, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03839771 · updated Sep 22, 2026